This content is only available within our institutional offering.
30 Sep 2019
BASILEA PHARMACEUTICA: Derazantinib shown to be effective in a broader iCCA population at ESMO 2019 | BUY | CHF73(+70%)
Sign in
This content is only available to commercial clients. Sign in if you have access or contact support@research-tree.com to set up a commercial account
This content is only available to commercial clients. Sign in if you have access or contact support@research-tree.com to set up a commercial account
BASILEA PHARMACEUTICA: Derazantinib shown to be effective in a broader iCCA population at ESMO 2019 | BUY | CHF73(+70%)
Basilea Pharmaceutica AG (0QNA:LON) | 4,620 0 0.0% | Mkt Cap: 605.3m
- Published:
30 Sep 2019 -
Author:
Victor Floc’h -
Pages:
3
BASILEA PHARMACEUTICA - BUY | CHF73(+70%)
Derazantinib shown to be effective in a broader iCCA population at ESMO 2019
FGFR2 mutations and amplifications patients benefit from Dera
Competitors do not address those patients
Extension of the ongoing clinical trial